ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
The effects of hyperprolactinemia and its control on metabolic diseases
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 127867" data-attributes="member: 13851"><p><strong>8. Five-year view</strong></p><p></p><p>Prolactin is a metabolic hormone, besides the well-known actions on fertility and reproduction. Dopaminergic tone plays a key role in the regulation of the metabolic system by modulating PRL secretion. Treatment of PRL excess with the dopamine-agonists bromocriptine and cabergoline has demonstrated to produce beneficial effects on gluco-insulinemic and lipid metabolism in obese diabetic patients, regardless of concomitant hyperprolactinemia, also providing promising results about their potential use as alternative or adjunctive treatment for type 2 diabetes mellitus. Future studies will better elucidate the burden and the differential role of PRL and dopamine-agonists on the modulation of metabolism in patients with hyperprolactinemia. </p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Key issues </span></strong></p><p></p><p>● PRL is a metabolic hormone. </p><p></p><p>● PRL excess induces hyperphagia and obesity, and promotes abnormalities in gluco-insulinemic and lipid profile, leading to metabolic syndrome in approximately one third of patients with hyperprolactinemia </p><p></p><p>● Medical treatment of hyperprolactinemia with dopamineagonists bromocriptine and cabergoline induces weight loss and improves lipid profile by reducing total and LDLcholesterol and triglycerides, and increasing HDL-cholesterol.</p><p></p><p> ● Fasting glucose and insulin levels reduce while on dopamine-agonists, together with a significant amelioration in insulin resistance and peripheral insulin sensitivity. </p><p></p><p>● Prevalence of metabolic syndrome significantly reduces after treatment with dopamine-agonists in patients with hyperprolactinemia. </p><p></p><p>● The metabolic improvement seen after treatment is independent on the degree of reduction in PRL levels, and should be ascribed to dopamine-agonists dosage, mainly in patients receiving cabergoline.</p><p></p><p> ● In male patients with concomitant hypogonadism, proper androgen replacement is mandatory to effectively ameliorate insulin resistance and metabolic syndrome.</p></blockquote><p></p>
[QUOTE="madman, post: 127867, member: 13851"] [B]8. Five-year view[/B] Prolactin is a metabolic hormone, besides the well-known actions on fertility and reproduction. Dopaminergic tone plays a key role in the regulation of the metabolic system by modulating PRL secretion. Treatment of PRL excess with the dopamine-agonists bromocriptine and cabergoline has demonstrated to produce beneficial effects on gluco-insulinemic and lipid metabolism in obese diabetic patients, regardless of concomitant hyperprolactinemia, also providing promising results about their potential use as alternative or adjunctive treatment for type 2 diabetes mellitus. Future studies will better elucidate the burden and the differential role of PRL and dopamine-agonists on the modulation of metabolism in patients with hyperprolactinemia. [B][COLOR=rgb(184, 49, 47)]Key issues [/COLOR][/B] ● PRL is a metabolic hormone. ● PRL excess induces hyperphagia and obesity, and promotes abnormalities in gluco-insulinemic and lipid profile, leading to metabolic syndrome in approximately one third of patients with hyperprolactinemia ● Medical treatment of hyperprolactinemia with dopamineagonists bromocriptine and cabergoline induces weight loss and improves lipid profile by reducing total and LDLcholesterol and triglycerides, and increasing HDL-cholesterol. ● Fasting glucose and insulin levels reduce while on dopamine-agonists, together with a significant amelioration in insulin resistance and peripheral insulin sensitivity. ● Prevalence of metabolic syndrome significantly reduces after treatment with dopamine-agonists in patients with hyperprolactinemia. ● The metabolic improvement seen after treatment is independent on the degree of reduction in PRL levels, and should be ascribed to dopamine-agonists dosage, mainly in patients receiving cabergoline. ● In male patients with concomitant hypogonadism, proper androgen replacement is mandatory to effectively ameliorate insulin resistance and metabolic syndrome. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
The effects of hyperprolactinemia and its control on metabolic diseases
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top